In 2002, the British pharmaceutical company Oxford BioMedica developed Repoxygen, a viral vector harboring a modified human EPO gene under the control of genes encoding proteins of oxygen homeostasis (e.g., HIF-1, HIF-2), as a potential drug for the treatment of anemia associated with the chemotherapy used in kidney cancer [130]. Here, EPO is linked to anemia.